Cemiplimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade

Description of Cemiplimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb - Research Grade

The Structure of Cemiplimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb

Cemiplimab Biosimilar is a monoclonal antibody (mAb) that targets the programmed cell death protein 1 (PD-1) receptor, also known as CD279. This receptor is found on the surface of immune cells, particularly T cells, and plays a crucial role in regulating the immune response. Cemiplimab Biosimilar is a biosimilar version of the therapeutic antibody cemiplimab, which is currently approved for the treatment of various cancers.

The structure of Cemiplimab Biosimilar is similar to that of cemiplimab, with both antibodies belonging to the immunoglobulin G (IgG) class. This class of antibodies is characterized by a Y-shaped structure, with two identical heavy chains and two identical light chains. The heavy chains are made up of constant and variable regions, while the light chains only have a variable region. The variable regions of both chains form the antigen-binding site, which is responsible for recognizing and binding to its target.

The Activity of Cemiplimab Biosimilar

Cemiplimab Biosimilar works by blocking the PD-1 receptor on T cells, which prevents the receptor from interacting with its ligands, PD-L1 and PD-L2. These ligands are found on the surface of cancer cells and other immune cells, and their interaction with PD-1 leads to the suppression of the immune response. By inhibiting this interaction, Cemiplimab Biosimilar allows the immune system to recognize and attack cancer cells.

In addition to blocking the PD-1 receptor, Cemiplimab Biosimilar also has the ability to enhance the activity of other immune cells, such as natural killer (NK) cells and macrophages. This is achieved through the activation of the immune signaling pathway, leading to the production of cytokines and chemokines that attract and activate these cells. This dual mechanism of action makes Cemiplimab Biosimilar a potent anti- cancer agent.

The Application of Cemiplimab Biosimilar

Cemiplimab Biosimilar is primarily used as a therapeutic agent for the treatment of various cancers, particularly those that have high levels of PD-L1 expression. These include melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma. It is typically used in combination with other cancer treatments, such as chemotherapy or radiation therapy.

In addition to its therapeutic use, Cemiplimab Biosimilar also has potential applications in research. As a biosimilar version of cemiplimab, it can be used as a tool for studying the role of the PD-1/PD-L1 pathway in cancer and other diseases. Its ability to enhance the activity of other immune cells also makes it a valuable tool for studying the immune response.

Conclusion

In summary, Cemiplimab Biosimilar is a monoclonal antibody that targets the PD-1 receptor on immune cells. Its Y-shaped structure allows it to bind to its target and block the interaction with its ligands, leading to the activation of the immune system and the suppression of cancer growth. This biosimilar version of cemiplimab has potential applications in both therapeutic and research settings, making it a valuable tool in the fight against cancer.

Cemiplimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Cemiplimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb (cat. No.PX-TA1524) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450